Biotronik today announced European market release of the Passeo-35 Xeo percutaneous transluminal angioplasty (PTA) balloon catheter. A company press release states that, compared to other available PTA balloons, the device offers physicians improved crossability, excellent trackability, and pushability in a wide range of sizes.

According to a recent analysis, the decision to delay operative repair of abdominal aortic aneurysm (AAA) should consider both patient age and local COVID-19 prevalence in addition to aneurysm size. Furthermore, endovascular aneurysm repair (EVAR) should be considered when possible due to a reduced risk of harm and lower resource utilisation.

Boston Scientific announced that the US Centers for Medicare and Medicaid Services (CMS) granted a new technology add-on payment (NTAP) for the Eluvia drug-eluting vascular stent system as part of the 2021 inpatient prospective payment system (IPPS).

According to a recent press release, MicroPort’s Minos ultra-low abdominal aortic aneurysm (AAA) stent graft and and Hercules low-profile thoracic aortic aneurysm (TAA) stent graft are now CE marked and available in Europe through Lombard Medical.

PQ Bypass has announced that they received breakthrough device designation from the US Food and Drug Administration (FDA) for the Detour system. The Detour system is the world’s first fully-percutaneous femoral-popliteal bypass device intended to treat extremely long, complex blockages in the superficial femoral artery (SFA).

The inaugural CX Aortic Vienna meeting will be livestreamed 8–11 September 2020 to an international, online audience, and will include registrant participation, interaction, and polling.

Concept Medical has announced the enrolment of the first patient in the FUTURE BTK (Randomised controlled trial of first sirolimus-coated balloon versus standard balloon angioplasty in the treatment of below-the-knee artery disease) trial. The index patient was successfully enrolled on 26 August 2020 in Singapore.

Guidelines for reducing the risk of stroke in patients undergoing heart surgery have been detailed in an American Heart Association (AHA) scientific statement, “Considerations for Reduction of Risk of Perioperative Stroke for Adult Patients Undergoing Cardiac and Thoracic Aortic Operations,” published in the journal Circulation.

Representation of women leading heart failure research remains limited, according to a study published in Circulation: Heart Failure, which may create a barrier to greater diversity among clinical trial participants.

The reliable outcomes of Getinge’s Advanta V12 have been reinforced by a new systematic literature review. A group of physicians from around the world joined to compare published studies of covered balloon-expandable (CBE) stents for aortoiliac occlusive disease (AIOD). “The Advanta V12 device stands out as the only solution with the most real-world, long-term data,” reads a Getinge press release.

A recent systematic review showed that randomised trials comparing different types of peripheral endovascular arterial intervention have a high level of heterogeneity in their antithrombotic regimens. It also revealed an increasing trend for use of dual antiplatelet therapy post intervention with no clear justification.

Just-published six-month results of the IN.PACT AV Access study show that drug-coated balloon (DCB) angioplasty is superior to standard angioplasty for the treatment of stenotic lesions in dysfunctional haemodialysis arteriovenous fistulas (AVFs). Furthermore, it was found to be non-inferior with respect to access circuit-related serious adverse events within 30 days.